VITASPRING BIOMEDICAL CO. LTD. financial statements (2021 and earlier)

Company profile

Business Address 2372 MORSE AVE. #950
IRVINE, CA 92614
State of Incorp.
Fiscal Year End January 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

10/31/2020
TTM
1/31/2020
1/31/2019
1/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments  05
Cash and cash equivalents  05
Inventory, net of allowances, customer advances and progress billings  86
Inventory  86
Prepaid expense  1 
Total current assets:  1011
Noncurrent Assets
Property, plant and equipment  12
Other undisclosed noncurrent assets  1011
Total noncurrent assets:  1113
Other undisclosed assets  (20)(22)
TOTAL ASSETS:  12
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities   10
Accounts payable   1
Employee-related liabilities   8
Debt  18 
Customer advances and deposits7
Total current liabilities:  1816
Noncurrent Liabilities
Other undisclosed noncurrent liabilities  1816
Total noncurrent liabilities:  1816
Other undisclosed liabilities  (25)(20)
Total liabilities:  1113
Stockholders' equity
Stockholders' equity attributable to parent, including: 18(7)(3)
Additional paid in capital 1818 
Accumulated other comprehensive loss (22)(29)(6)
Retained earnings 22  
Other undisclosed stockholders' equity attributable to parent  43
Other undisclosed stockholders' equity  (11) 
Total stockholders' equity: 18(18)(3)
TOTAL LIABILITIES AND EQUITY: 18(7)9

Income statement (P&L) ($ in thousands)

10/31/2020
TTM
1/31/2020
1/31/2019
1/31/2018
Revenues 151716
Other operating income 26  
Cost of revenue
(Cost of Goods and Services Sold)
 (13) (5)
Other undisclosed gross profit  (3) 
Gross profit: 21411
Operating expenses (21)3618
Other undisclosed operating loss  (72) 
Operating income (loss): (19)(22)29
Nonoperating income 8  
Other nonoperating income 9  
Interest and debt expense 18  
Other undisclosed loss from continuing operations before equity method investments, income taxes (1)  
Income (loss) from continuing operations before equity method investments, income taxes: 7(22)29
Income from equity method investments 7  
Income (loss) from continuing operations: 14(22)29
Income from discontinued operations 19  
Income (loss) before gain (loss) on sale of properties: 33(22)29
Other undisclosed net loss   (35)
Net income (loss): 33(22)(6)
Other undisclosed net loss attributable to parent (26)  
Net income (loss) available to common stockholders, basic: 7(22)(6)
Other undisclosed net income available to common stockholders, diluted   3,006
Net income (loss) available to common stockholders, diluted: 7(22)3,000

Comprehensive Income ($ in thousands)

10/31/2020
TTM
1/31/2020
1/31/2019
1/31/2018
Net income (loss): 33(22)(6)
Comprehensive income (loss), net of tax, attributable to parent: 33(22)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: